Related Experiment Videos
Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial
A M Guerguerian1, M Gauthier, M H Lebel
1Pediatric Intensive Care Unit, Division of Infectious Diseases, Department of Pediatrics, Sainte-Justine Hospital, Université de Montréal, Montreal, Quebec, Canada.
American Journal of Respiratory and Critical Care Medicine
|September 3, 1999
Summary
Aerosolized ribavirin did not effectively reduce ventilation duration for infants with respiratory syncytial virus (RSV) bronchiolitis. This clinical trial found no significant benefits in treatment course or hospitalization for ventilated infants receiving ribavirin.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Respiratory syncytial virus (RSV) bronchiolitis is a common cause of respiratory distress in infants.
- Mechanical ventilation is often required for severe cases, necessitating effective treatment strategies.
Purpose of the Study:
- To evaluate the clinical effectiveness of aerosolized ribavirin in infants requiring ventilation for RSV bronchiolitis.
- To determine if ribavirin reduces the duration of mechanical ventilation and hospitalization.
Main Methods:
- A prospective, double-blind, placebo-controlled trial was conducted.
- 41 infants requiring ventilation for RSV bronchiolitis were randomized to receive either aerosolized ribavirin or placebo.
- Treatment was administered for up to 7 days or until extubation.
Main Results:
- No significant differences were observed in the length of ventilation between the ribavirin and placebo groups (102.16 vs. 126.28 hours).
- There were no significant differences in aerosol therapy duration, intensive care unit stay, oxygen therapy, or hospitalization length.
- Aerosolized ribavirin was well-tolerated, and no deaths occurred during the study.
Conclusions:
- Aerosolized ribavirin is not effective in reducing the duration of ventilation or the overall course of illness in infants with RSV bronchiolitis who require mechanical ventilation.
- Current evidence does not support the use of aerosolized ribavirin for this patient population.